DINA 003
Alternative Names: DINA-003Latest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator DiNAQOR AG
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiomyopathies
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Cardiomyopathies in Switzerland (Intracardiac)
- 31 Jan 2020 DiNAQOR has patents pending for DINA 003 (DiNAQOR pipeline, January 2020)
- 31 Jan 2020 Early research in Cardiomyopathies in Switzerland (Intracardiac) (DiNAQOR pipeline, January 2020)